Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks.
-
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
Zejula is the only monotherapy available for women who do not have a BRCA mutation.
-
Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps
Pivotal data support regulatory filing for additional eosinophil-driven disease
-
GSK completes divestment of Horlicks and other Consumer Healthcare nutrition products in India and certain other markets
GSK today announced the completion of its divestment of Horlicks and other Consumer Healthcare nutrition products in India to Unilever.
-
Zejula (niraparib) is the first and only once-daily PARP inhibitor FDA-approved as a first-line monotherapy maintenance treatment for women with advanced ovarian cancer regardless of biomarker status
GlaxoSmithKline plc today announced the U.S. FDA approved the company’s supplemental New Drug Application (sNDA) of Zejula (niraparib).
-
GSK appoints Charles Bancroft to the Board as a Non-Executive Director
GlaxoSmithKline plc today announced that Charles Bancroft will join the Board of the Company as a Non-Executive Director on 1 May 2020.
-
ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV
ViiV Healthcare, today announced that Health Canada has approved CABENUVA.
-
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen in adults living with HIV-1
ViiV Healthcare presents positive long-term data from phase III study
-
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
ViiV Healthcare presents positive 48-week data from phase III study
-
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
-
GSK receives EC approval for the sale of ThermaCare
GSK receives EC approval for the sale of ThermaCare
-
FDA approves GSK’s Advil Dual Action with Acetaminophen for over-the-counter use in the United States
First combination of ibuprofen and acetaminophen for pain relief to be available OTC in 2020
-
GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
-
First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
-
European Medicines Agency accepts submission of GSK’s Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
Submission based on data from the Phase III PRIMA clinical study.
-
U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib)
-
Clover and GSK announce research collaboration to evaluate coronavirus (COVID-19) vaccine candidate with pandemic adjuvant system
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
-
FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the United States
U.S. Food and Drug Administration (FDA) has approved Voltaren Arthritis Pain as an over-the-counter (OTC) product.
-
GSK delivers 2019 sales of £33.8 billion +10% AER, +8% CER (Pro-forma +4% CER*)
Total EPS 93.9p; +27% AER; +23% CER; Adjusted EPS 123.9p +4% AER, +1% CER
-
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
GSK to make adjuvant technology available to support rapid development of candidate vaccines
